Top 5 Stock Picks of Srini Akkaraju and Michael Dybbs’ Samsara BioCapital

3. Instil Bio, Inc. (NASDAQ:TIL)

Samsara BioCapital’s Stake Value: $38.34 million

Percentage of Samsara BioCapital’s 13F Portfolio: 6.01%

Number of Hedge Fund Holders: 11

Instil Bio, Inc. (NASDAQ:TIL) is a publicly held biotechnology company based in Texas. It develops treatments using cell therapy against cancer, specifically utilizing autologous tumor infiltrating-lymphocytes (TIL).

On December 8, Baird analyst Jack Allen assumed coverage of Instil Bio, Inc. (NASDAQ:TIL) stock with an Outperform rating and the price target of $34.